Candesartan cilexetil has shown potent and long-lasting antihypertensive effects in clinical trials and in several animal models of hypertension. In spontaneously hypertensive rats, the duration of the antihypertensive effect of candesartan cilexetil was compared to those of losartan, valsartan, eprosartan, and irbesartan at the same degree of maximal blood pressure reduction. A single oral dose of candesartan cilexetil at 0.3 mg/kg reduced maximal blood pressure by about 25 mm Hg, and the antihypertensive effect of candesartan cilexetil lasted the longest, continuing for more than 1 week, without an effect on circadian rhythm. In a rabbit aortic preparation, candesartan, active form of candesartan cilexetil, decreased the maximal contractile response of angiotensin II. This inhibitory mode was different from that of
Introduction
The final purpose of antihypertensive treatment is to reduce morbidity and mortality from cardiovascular disease associated with hypertension. To achieve this aim, well-tolerated antihypertensive agents with long durations of action are required. The renin-angiotensin system is a cascade of enzymatic reactions leading to the formation of its primary effective molecule, angiotensin II. Angiotensin II is a potent vasoconstrictor, growth promoter, and fibrosis promoter. It facilitates vasoconstriction, increases renal retention volume, and leads to vascular growth that is associated with hypertension. 1, 2 An inhibitor of this system would be expected to have an efficacy not only for treatment of hypertension, but also for treatment of various cardiovascular and renal diseases. The angiotensin II-receptor antagonists provide a specific blockade of the reninangiotensin system by competing directly with angiotensin II at its receptor. These drugs are therefore highly specific and effective, as they block the effects of angiotensin II produced by both the angiotensin-converting enzyme (ACE) and alternative angiotensin II-generating pathways. 3, 4 In addition, because the angiotensin II antagonists do not affect bradykinin, substance P, or tachykinin metabolism, Correspondence: Yoshiyuki Inada, Pharmaceutical Research Division, Takeda Chemical Industries Ltd, 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 53, Japan other angiotensin II-receptor antagonists, and showed a shift to the right in the angiotensin II-induced contraction curve and/or a small depression of the maximal response. In kinetic studies using bovine adrenal cortical membrane and tritiated candesartan, both receptor association and dissociation were found to be slow. The dissociation rate of tritiated candesartan binding (t 1/2 = 66 min) was five times slower than that of radiolabelled angiotensin II binding (t 1/2 = 12 min). The insurmountable inhibition of candesartan in vascular contraction is the result of its tight binding and slow dissociation from angiotensin II AT 1 receptors. These characteristics are related to the potency and long duration of action in candesartan cilexetil.
they do not cause the class-specific side effects associated with ACE inhibitors. 5 The potential of antihypertensive therapy to reduce morbidity and mortality has been demonstrated in clinical studies involving large numbers of patients. However, it is equally clear that the potential of antihypertensive therapy is not fully realised, and that the complicated results are dependent on the drug profiles. Recently, many angiotensin II-receptor antagonists have been used clinically. 6, 7 Angiotensin II receptor antagonists vary in their receptor-binding characteristics, and therefore, in their potencies and pharmacologic properties.
Candesartan cilexetil, developed by Takeda Chemical Industries Ltd, Japan, is the prodrug of candesartan, a novel, specific, and competitive antagonist of the angiotensin II type 1 (AT 1 ) receptors. [8] [9] [10] [11] Candesartan cilexetil showed antihypertensive action in clinical trials and in animal models of hypertension. 6, 7, 12, 13 In this report, we compare the duration of the antihypertensive effect of candesartan cilexetil with that of other AT 1 -receptor antagonists. We also review the relationship between duration of action and mode of inhibition of angiotensin II-induced effects.
Antihypertensive effects in spontaneously hypertensive rats
This study compared the duration of the antihypertensive action in spontaneously hypertensive rats (20 to 32 weeks of age). Blood pressure was meas- ured every 5 min by the telemetry method. The values of blood pressure were expressed by the average for each 30 min (mean of six measurements). As shown in Figure 1 , candesartan cilexetil, 0.3 to 10 mg/kg p.o., dose dependently lowered blood pressure, with a prolonged duration at doses of 1 mg/kg and greater.
The maximal reduction of blood pressure was calculated from the mean blood pressure of each 30-min period minus the average of the mean blood pressure on the previous day of administration. The duration of action was calculated as the area over the curve for 1 week after the administration, divided by the maximal reduction of blood pressure. The maximal reductions of blood pressure with candesartan cilexetil at 0.1, 0.3, 1, and 10 mg/kg p.o. were as follows: −23.3 ± 1.9, −28.5 ± 1.4, −31.5 ± 1.8, and −40.4 ± 2.2 (mean ± s.e.m.), respectively. At a dose of 0.3 mg/kg, candesartan cilexetil produced a maximal blood pressure reduction similar to those of losartan 10 mg/kg, eprosartan 100 mg/kg, irbesartan 30 mg/kg, and valsartan 10 mg/kg on day 1 (Figure 2a) . At a dose of 1 mg/kg, candesartan cilexe- til produced a maximal blood pressure reduction similar to those of losartan 30 mg/kg and irbesartan 100 mg/kg (Figure 2a ). The antihypertensive action of candesartan cilexetil at 0.3 mg/kg and 1 mg/kg persisted for over 20 h, and for nearly 60 h, respectively, and was more prolonged than for the other angiotensin II-receptor antagonists (Figure 2b ).
Inhibitory effects on the contractile response induced by angiotensin II in rabbit aortic strips
The contractile responses in helical strips of rabbit thorathic aorta induced by angiotensin II were measured using a force-displacement transducer. The mean force development in responses to increasing concentrations of angiotensin II was recorded with and without AT 1 -receptor antagonist. The response to angiotensin II in the presence of AT 1 -receptor antagonist was expressed as percentage of the maximal response (100%) to angiotensin II that was obtained prior to the AT 1 -receptor antagonist incubation period.
As shown in Figure 3 , candesartan inhibited the angiotensin II-induced contractile response of rabbit aorta at very low concentrations (0.1 nmol/L). 11 Candesartan at 1 nmol/L almost completely inhibited the angiotensin II-induced contractile response of the strip, indicating non-competitive antagonism (insurmountable inhibition). Irbesartan at 1 to 100 nmol/L, and losartan at 10 to 100 nmol/L, shifted the angiotensin II-induced contractile curve to the right in a parallel fashion, with no decrease of the maximal response (surmountable inhibition). 11, 14 These compounds showed competitive antagonism. EXP3174, an active metabolite of losartan, at a concentration of 0.01 to 1 nmol/L, caused a shift to the right in the angiotensin II concentration-contractile response curve, but with a small depression of the maximal response, which showed a mixed antagonism with both competitive and non-competitive types (insurmountable inhibition). 11, 14 The inhibition of the angiotensin II (3 nmol/L)-induced contraction by the pretreatment with candesartan at 0.1 to 1 nmol/L for 60 min was not reco- vered 2 h after washing in the rat portal vein. 15 In contrast, after 2 h of washing, the inhibition of the angiotensin II-induced contraction by pretreatment with irbesartan, losartan, and EXP3174 was almost reversed. Thus, the duration of the inhibitory effect of candesartan on contractile response induced by angiotensin II is longer than that of irbesartan, losartan, or EXP3174. Human AT 1 receptors were isolated from a human heart cDNA library and transfected into COS-7 cells. 16 Crude membrane fractions from the cells were used for the assay of binding inhibition of AT 1 ]angiotensin II in human AT 1 receptors at an IC 50 value of 3.0 × 10 −9 mol/L. Candesartan was the most potent of the angiotensin II receptor antagonists tested. The inhibitory potencies of these agents were in the following order: candesartan у irbesartan, EXP3174 Ͼ eprosartan and valsartan. 
Discussion
Candesartan provides a highly potent, long-acting, and selective angiotensin II type 1 (AT 1 ) receptor blockade. 10, 11, 17, 18 It is administered orally as the inactive prodrug, candesartan cilexetil, which is rapidly and completely converted to candesartan during gastrointestinal absorption. 19 Candesartan cilexetil has been shown to possess potent and longlasting antihypertensive effects in several animal models and clinical trials of patients with hypertension. 6, 7, 12, 13, 20 In spontaneously hypertensive rats, single oral doses of candesartan cilexetil (0.1-10 mg/kg) reduced blood pressure by 25 to 40 mm Hg for more than 10 h, and the effect at 1 mg/kg was pronounced even after 48 h (−30 mm Hg).
Other angiotensin II receptor antagonists require a much higher dose to induce a similar antihypertensive effect as that of candesartan cilexetil 0.3 mg/kg (losartan, 1 mg/kg; irbesartan, 30 mg/kg; eprosartan, 100 mg/kg; and valsartan, 10 mg/kg) ( Figure 2 ). These differences of the doses required to produce similar antihypertensive effects in spontaneously hypertensive rats are larger than the differences found in IC 50 19, 21 it is thought that a more important factor than the difference in IC 50 values exists to explain these differences in antihypertensive efficacy.
In spontaneously hypertensive rats, oral administration of candesartan cilexetil at 1 mg/kg for 2 weeks reduced blood pressure by 30 to 50 mm Hg for more than 24 h. The antihypertensive effects of candesartan cilexetil correlated well with the ex vivo inhibition of the drug on angiotensin II-induced contractile responses in aortic strips prepared from the treated rats. 12 Specifically, candesartan cilexetil inhibited the angiotensin II-induced contractile responses in the aorta isolated 5 and 24 h after oral administration, when the blood pressure was significantly reduced in vivo. This ex vivo inhibitory effect, however, was not evident when the blood pressure-lowering effects had disappeared. These findings suggest that inhibition of the action of angiotensin II at its receptor site on the vascular wall determines the degree and time course of the antihypertensive effects of candesartan.
In aortic strip preparations from the rabbit (Figure  3a) , candesartan has been shown to produce a clear, dose-dependent reduction in the maximum contraction of vascular strips exposed to angiotensin II. In contrast, losartan and irbesartan shifted the contractile response curve to the right, without affecting the maximal response.
14 This indicates a competitiveinhibiting profile, in which angiotensin II is able to displace losartan and irbesartan at the AT 1 receptor. EXP3174, the active metabolite of losartan, showed a mixed-inhibiting profile. It has been reported eprosartan produced surmountable (competitive) inhibition, 22 but valsartan, 23 and irbesartan 24 produced insurmountable inhibitions. In these reports, irbesartan and valsartan showed insurmountable inhibition, but they had a mixed type of competitive and non-competitive inhibition, and were not totally non-competitive. Furthermore, following washings, irbesartan was shown to have a competitive manner of inhibition after 22 h of equilibrium had been reached. 14 The antihypertensive effect of candesartan cilexetil in spontaneously hypertensive rats was more prolonged than that of other agents. The duration of antihypertensive action is thought to be related to the inhibitory manner of the non-competitive inhibition; such inhibition is thought to produce a longer effect on the contractile response induced by angiotensin II in vascular preparations in vitro. 15 In in vitro kinetic studies, 17 27 Aiyar et al 28 showed that the dissociation rate of SB203220, which exhibits a partial insurmountable antagonism of angiotensin II-induced contraction in rabbit aorta, is slower than that of SK&F108566, a surmountable antagonist. These findings suggest that the insurmountable antagonism caused by candesartan is attributable to its slow dissociation from angiotensin AT 1 receptors.
Recent attention has focused on the relationship between the duration of antihypertensive action and the prevention of end-organ damage. Candesartan cilexetil (1-10 mg/kg) completely prevented the incidence of stroke, and reduced left ventricular mass and nephrosclerosis in stroke-prone spontaneously hypertensive rats. 29 These doses of candesartan cilexetil also markedly reduced blood pressure. However, even at a lower dose of 0.1 mg/kg, which had no effect on blood pressure, candesartan cilexetil reduced the incidence of stroke, and significantly reduced urinary albumin excretion. Furthermore, candesartan cilexetil prevented cerebral and renal injury in a renin-angiotensin-independent model, the DOCA/salt hypertensive rat. 30 The expression of various genes is up-regulated in cardiovascular tissues of stroke-prone spontaneously hypertensive rats and DOCA/salt hypertensive rats. Candesartan cilexetil suppressed expression of the genes for transforming growth factor-␤1 and the extracellular matrix proteins in the kidney, heart, and blood vessels. [31] [32] [33] These inhibitory effects on gene expression may contribute to the prevention of hypertension-induced cerebral and renal injury, cardiac hypertrophy, and vascular thickening conferred by candesartan cilexetil, irrespective of any action of the drug on systemic haemodynamics.
The tight and long-lasting binding of candesartan at the AT 1 receptor found during in vitro studies has been confirmed in human subjects. For example, in a study of 27 healthy, male volunteers, Delacretaz and colleagues concluded that candesartan cilexetil is a well tolerated, potent, and long-lasting antagonist of angiotensin II. 34 In this study, candesartan cilexetil (1, 2, 4, or 8 mg once daily) produced a dose-dependent reduction in the rise of systolic blood pressure in response to an intravenous infusion of angiotensin II. Importantly, the reduction in blood pressure produced by candesartan cilexetil was found to be maintained throughout the 24-h dosing period, despite a fall in the plasma concentration of candesartan. This phenomenon reflects the tight binding of candesartan at the AT 1 receptor and slow dissociation from it.
In conclusion, the present studies have indicated that candesartan binds tightly and dissociates slowly for the binding sites in AT 1 receptors. The insurmountable inhibition of candesartan in contractions induced by angiotensin II may be attributed to their tight binding and slow dissociation properties for AT 1 receptor, and these characteristics may be related to the long-lasting antihypertensive effect of candesartan cilexetil in vivo. These longlasting properties of candesartan cilexetil might be beneficial for the treatment of hypertension and related diseases.
